<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
62856-220-01
</NDCCode>
<PackageDescription>
1 SYRINGE, PLASTIC in 1 CARTON (62856-220-01) / 1.8 mL in 1 SYRINGE, PLASTIC (62856-220-10)
</PackageDescription>
<NDC11Code>
62856-0220-01
</NDC11Code>
<ProductNDC>
62856-220
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Lecanemab Autoinjector
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Lecanemab-irmb
</NonProprietaryName>
<DosageFormName>
INJECTION, SOLUTION
</DosageFormName>
<RouteName>
SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20250829
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
BLA
</MarketingCategoryName>
<ApplicationNumber>
BLA761375
</ApplicationNumber>
<LabelerName>
Eisai Inc.
</LabelerName>
<SubstanceName>
LECANEMAB-IRMB
</SubstanceName>
<StrengthNumber>
200
</StrengthNumber>
<StrengthUnit>
mg/mL
</StrengthUnit>
<Pharm_Classes>
Amyloid Beta-directed Antibody Interactions [MoA], Amyloid Beta-directed Antibody [EPC]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2026-02-02
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20271231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20250829
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>